Overview
Investment in women’s health is accelerating as founders build solutions that address longstanding gaps in care. These nine startups are developing technologies and care models that span fertility, maternal health, menopause, and healthy aging.
Recent growth and investment interest in the health space for solutions affecting women is promising. According to a Silicon Valley Bank report, women’s health investment reached a record $2.6 billion in 2024, which was a 55% increase from 2023. Hope Khoury, healthcare executive and Chief Operating Officer at the product innovation and development firm Go Vertical ICM, says women’s health is increasingly recognized as an “opportunity gap.”
“World Economic Forum’s 2026 outlook notes women’s health has historically captured only about 6% of private healthcare investment, despite representing about half the population—suggesting ‘catch-up’ growth potential,” she says. “Macro-economic framing has sharpened investor attention: McKinsey/WEF’s work sizes the women’s health gap as a major global economic opportunity, often referenced as ~$1T annually.”
Khoury says the market is expanding beyond reproductive women’s health toward a lifespan view that includes adolescence, fertility, pregnancy/postpartum, menopause and healthy aging, which she notes is a meaningful structural shift.
She anticipates demand to continue across the country due to the following drivers:
Unmet need and system constraints including access. “Maternal-care access challenges are well documented (e.g., large shares of counties lacking adequate maternity services), pushing adoption of tech-enabled and hybrid care models,” says Khoury.
Consumer normalization. Because women are strong digital health users, and utilization is no longer “niche” behavior, Khoury says this supports sustained demand for women’s health products that remove friction and improve access.
Institutional and employer pull. “Large purchasers including employers, payers, systems, increasingly look for ROI-linked solutions [such as] reduced complications, fewer ER visits, improved adherence, retention, which supports expansion beyond coastal hubs,” Khoury says.
Growth trajectory will be strongest where startups can prove outcomes and integrate with reimbursement or enterprise distribution, rather than rely solely on DTC demand. Khoury believes the biotech/health companies across women’s health that are most successful demonstrate clinical credibility, distribution, and measurable outcomes.
“Capital is still under-allocated relative to need, which often creates an inefficiency: companies with strong clinical proof plus distribution can become category leaders quickly,” says Khoury. She anticipates the next wave of winners to be those that close diagnostic delays, integrate care delivery, and demonstrate measurable outcomes, “because that’s what unlocks reimbursement and enterprise adoption.”
Here is a look at some women’s health companies making an impact.
Gameto
Cellular engineering for fertility care including de‑risking in vitro maturation and advancing programs in ovarian health and menopause.
HQ: Austin, TX, and New York, NY
Year founded: 2020
Origin Story: After Dina Radenkovic and Martin Varsavsky founded the company, they worked with a lab at Harvard’s Wyss Institute to research cell engineering. Their work together inspired the science to mature eggs outside a woman’s body, and led to the development of their product, Fertilo.
Key Leaders:Dina Turner, Co-Founder and CEO; Christian Kramme, PhD, Chief Scientific Officer; Gus Haddad, MD, Chief Medical Officer
Number of employees: ~50
Stage: Series C
Financial Snapshot: Raised a total of ~$127 million total
Notable Investors: Overwater Ventures; Insight Partners; RA Capital; Two Sigma Ventures; BOLD Capital Partners; Future Ventures; Ingeborg Investments; Arcadia Investment Partners; PAGS Group; Pontiva Healthcare Partners; Portfolia
Key Products: Fertilo, a therapeutic for IVF and egg freezing; Ameno, a cell therapy to treat menopause.
Recent Highlights: In January 2026, the company announced that it had exclusively licensed additional intellectual property from Harvard University related to the induction of meiosis in human cells. The company noted that it will integrate the meiosis-induction approach with its proprietary ovarian organoid (“ovaroid”) platform to induce human oogonia to enter early meiotic stages in vitro.
Evvy
Female biomarkers and vaginal microbiome discovery
HQ: New York, NY
Year Founded: 2020
Key Leaders: Priyanka Jain, Co-Founder and CEO; Laine Bruzek, Co-Founder and Chief Marketing Officer; Pita Navarro, Co-Founder and Chief Science Officer; Kate McLean, MD, Chief Medical Advisor
Number of Employees: ~50
Stage: Series A
Financial Snapshot: Raised a total of $19 million
Notable Investors: Ingeborg Investments, Left Lane Capital, RH Capital, Amboy Street Ventures, BBG Ventures
Key Products: Vaginal Health Test, an at-home vaginal microbiome test that uses metagenomic sequencing
Recent Highlights:In October 2025, Evvy announced that over 75,000 patients and 2,000 healthcare providers use its vaginal microbiome testing and care platform. And, in December 2025, the company launched its at-home clinical care program.
Fate Therapeutics
Cellular immunotherapies
HQ: San Diego, CA
Year Founded: 2007
Origin Story: The company originated from research out of Mass General, Stanford University, Harvard University, the University of Washington, and The Scripps Research Institute.
Key Leaders: Bahram (Bob) Valamehr, PhD, President and Chief Executive Officer; Cindy Tahl, JD, Chief Legal and Compliance Officer; Kamal Adawi, MBA, Chief Financial Officer
Number of Employees: ~180
Stage: Public
Financial Snapshot: The company’s market cap was $0.15 billion as of March 2026.
Key Products: FT819, Autologous CAR T-cell therapy for hematologic malignancies, including refractory cancers; ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.
Recent Highlights: In February 2026, the company announced that the FT819-102 Phase 1 clinical trial is enrolling in 16 clinical sites across the U.S., U.K. and E.U, and that it successfully treated patients in FT819-102 clinical trial as outpatient treatment.
FamilyWell Health
Digital mental health platform for women across reproductive life stages, including fertility, pregnancy/postpartum, and perimenopause/menopause
HQ: Boston, MA
Year Founded: 2022
Origin Story: Neonatologist Jessica Gaulton, MD, founded the company after experiencing postpartum depression.
Key Leaders: Jessica Gaulton, MD, Founder and CEO; Bridget Stewart, COO; Kate O’Leary, Chief Product Officer; Teryn Henning, Chief of Staff; Marissa Caan, MD, Medical Director
Number of Employees: ~45
Stage: Series A
Financial Snapshot: Closed an $8M Series A in November, 2025
Notable Investors: New Markets Venture Partners; .406 Venture; GreyMatter Capital; The Alix Foundation; The Donna Fund; The Lee Foundation
Key Products: AI-enabled digital platform that integrates maternal mental health support directly into OB/GYN care using collaborative care billing codes.
Recent Highlights: In 2025, the company was recognized as one of the fastest growing startups in Boston.
AOA Dx
Tumor marker gangliosides and AI-enabled technology to detect ovarian cancer
HQ: Denver, CO
Year Founded: 2020
Origin Story: Founded by three entrepreneurs who had been working together for over 10 years within the women’s health industry.
Key Leaders: Oriana Papin-Zoghbi, Co-Founder and CEO; Alex Fisher, Co-Founder and COO; Anna Jeter, Co-Founder and Chief Regulatory Officer; Abigail McElhinny, PhD, Chief Scientific Officer
Number of Employees: ~20
Stage: Series A
Financial Snapshot: Closed a $17 million Series A in October, 2023
Notable Investors: Foreground Capital, Harper Ventures, Mount McKinley Investment, 2468 Ventures, Adaptive Capital Partners
Key Products: AKRIVIS GD test, an AI‑enhanced multi‑omic blood test for early ovarian cancer detection using lipidomics and other biomarkers. GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers by using a non-invasive blood test.
Recent Highlights: In January 2026, AOA Dx released the first comprehensive analysis of realized exit outcomes across women’s health over the past 25 years. In October 2025, the company announced peer-reviewed clinical evidence published in Diagnostics that found its multi-omic model achieved 94.8% sensitivity in early-stage OC and 94.4% across all stages and subtypes, a significant improvement over the current standard of care biomarker, CA125.
Celmatix Therapeutics
Precision therapeutics for ovarian biology, ovarian aging, PCOS, and endometriosis
HQ: New York, NY
Year Founded: 2009
Origin Story: After completing her post-doc focused on mammalian reproduction at the University of Cambridge, Piraye Yurttas Beim was inspired to found Celmatix in order to accelerate precision medicine innovations in women’s health.
Key Leaders: Piraye Yurttas Beim, PhD, Founder and CEO; Stephen Palmer, PhD, CSO; Adrienne Day, PhD, CBO; Keith Dewedoff, CFO
Number of Employees: ~20
Stage: Series A
Financial Snapshot: The company has raised over $43 million to date
Notable Investors: GLG, Evotec, Brainchild, Springboard Enterprises, ARPH-H
Key Products: AMHR2 agonist program focused on ovarian aging, an oral FSH for infertility, and a JNK inhibitor program for endometriosis
Recent Highlights:In October 2024, the company received $3.5 million in funding over two years through the Sprint for Women’s Health spark track for early-stage research efforts. And, in January 2025, Celmatix announced its novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation.
Dare Bioscience Inc.
Non-hormonal contraception and menopause symptom management
HQ: San Diego, CA
Year Founded: 2005
Key Leaders: Sabrina Martucci Johnson, President and CEO; David Friend, PhD, Chief Scientific Officer; Annie Thurman, MD, Medical Director
Number of Employees: ~20
Stage: Public
Financial Snapshot: The company’s market cap was $21.86 million as of March 2026.
Key Products: XACIATO (clindamycin phosphate) vaginal gel, FDA approved; Ovaprene hormone-free; monthly contraception in pivotal phase 3 study
Recent Highlights: In February 2026, Dare Bioscience announced FDA clearance of IND for Phase 2 Clinical Study of DARE-HPV, a potential treatment for persistent high-risk HPV infection, the most common cause of cervical cancer. In February 2026, the company also announced that telehealth is now available for its topical arousal cream DARE to Play Sildenafil Cream.
Raydiant Oxymetry
Fetal monitoring and uterine bleeding control
HQ: San Ramon, CA
Year Founded: 2016
Origin Story: Founded by Neil P. Ray, MD, a pediatric anesthesiologist, who wanted to help identify fetal distress and avoid medically unnecessary Cesarean sections.
Key Leaders: Michael Nagel, CEO; Russ DeLonzor, COO and President; Debra A. (Young) Snowdale, CFO; Mark Rosen, MD, Chief Medical Officer; Paul Stetson, PhD, Chief Science Officer
Number of Employees: ~30
Stage: Series B
Financial Snapshot: Oversubscribed a $7.5 million Series A3 extension round and received a $1 million grant from the Bill & Melinda Gates Foundation
Notable Investors: Cross Border, Steelsky Ventures, FemHealth Ventures, V Capital, Gates Foundation, Catalytic Impact Foundation, March of Dimes, Impact Assets, Cross Border Impact Ventures
Key Products: EchoGo uses artificial intelligence and cardiac ultrasound to diagnose heart failure; Lumerah is a transabdominal patch designed to monitor fetal pulse oximetry during childbirth; Daisy is a vacuum-assisted cervical drain that effectively removes excess blood from the uterus following various OB-GYN procedures, including C-sections, helping to improve recovery and reduce complications.
Recent Highlights: In November 2025, the company announced its Investigational Device Exemption (IDE) Pilot Study at Louisiana State University Health Shreveport, which will collect fetal pulse oximetry waveforms using a transvaginal sensor that can rest on the baby’s cheek, forehead or temple. In October 2025, Raydiant Oximetry completed a 35-patient Early Feasibility Study at Eastern Virginia Medical School at Old Dominion University.
Madorra
Medical equipment for vaginal health
HQ: Portland, OR
Year Founded: 2014
Key Leaders: Holly Rockweiler, Co-Founder & CEO; Bryan Flaherty, CTO; Stephanie Kaplan, COO; Julia Willaims, CFO
Number of Employees: ~10
Stage: Series A
Financial Snapshot: Some sources report the company has $5 million in revenue
Notable Investors: Matter Ventures, K2X, Samothrace Partners, P&G Ventures, Aletta Angels
Key Products: Madorra Therapy System to treat vaginal atrophy in breast cancer survivors
Recent Highlights: In 2024, the company was awarded $2 million from the America’s Seed Fund for its Madorra Therapy System.
